News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
47 Results
Type
Article (8)
Press Release (39)
Section
Business (22)
Deals (2)
Drug Development (12)
Job Trends (1)
News (35)
Tag
Academia (1)
Alliances (9)
Best Places to Work (1)
Clinical research (9)
Earnings (3)
Events (9)
Mergers & acquisitions (2)
People (10)
Phase I (7)
Phase II (2)
Phase III (1)
Preclinical (2)
Date
2023 (1)
2022 (1)
2020 (3)
2019 (4)
2018 (7)
2017 (5)
2016 (7)
2015 (1)
2014 (1)
2013 (1)
2012 (3)
2011 (2)
2010 (1)
Location
Asia (2)
Australia (1)
Europe (30)
47 Results for "vaximm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
NEC OncoImmunity announced that the companies have signed an agreement under which NOI will acquire all of VAXIMM’s neoantigen program assets.
March 8, 2022
·
6 min read
VAXIMM to Participate at Upcoming Industry Events
VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced today that the Company will participate in several industry events in the coming months.
January 31, 2020
·
3 min read
Business
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Clinical trial collaboration agreement leverages NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology
November 11, 2019
·
3 min read
VAXIMM Announces Presentations at Upcoming Industry and Scientific Event
VAXIMM AG announced that the Company will participate in several events around the globe in the coming months.
September 15, 2019
·
2 min read
VAXIMM Announces Presentations at Upcoming Industry and Scientific Events on October and November 2018
VAXIMM AG today announced that the Company will participate in several upcoming events in the fourth quarter of 2018.
September 30, 2018
·
2 min read
VAXIMM Announces Presentations at ASCO 2019 and Other Upcoming Industry and Scientific Events
VAXIMM AG announced that the Company will present an abstract about the design of its ongoing trial in patients with glioblastoma with VXM01 oral T-cell immunotherapy in combination with the anti-PD-L1 checkpoint inhibitor avelumab at the 2019 American Society of Clinical Oncology Annual Meeting.
April 18, 2019
·
2 min read
Business
VAXIMM Announces Regional Development and Commercialization Agreement with China Medical System Holdings
CMS gains exclusive rights to current VAXIMM pipeline and option for future programs for China and other Asian countries, ex-Japan
September 21, 2018
·
3 min read
VAXIMM AG Announces Presentations at Upcoming Industry and Scientific Events
VAXIMM today announced that the Company will participate in several upcoming events in the first quarter of 2018.
January 18, 2018
·
3 min read
Drug Development
VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma
VAXIMM AG, announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma.
December 16, 2018
·
7 min read
VAXIMM Announces Presentations At Upcoming Industry And Scientific Events
May 3, 2017
·
3 min read
1 of 5
Next
